Company intelligence / Profile preview

Weimi Bio-Tech

Guangzhou, Guangdong, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Weimi Bio-Tech is a commercial-stage, high-tech IVD manufacturer with multiple diagnostic assay platforms (immunoassay, molecular, chemiluminescence) and a broad product portfolio targeting diseases such as cardiovascular disease, cancer, inflammation, and COVID-19; it has a strong R&D base and collaborations with academic institutions, and has raised multiple funding rounds[1][2].

Therapeutic areas: ImmunologyEndocrinologyNephrologyInfectious DiseasesCardiovascularOncologyWomen's Health
Modalities: DeviceDiagnostic reagentBiologicSmall molecule
Industry: Molecular Diagnostics

Partnerships

Guangzhou KingMed Diagnostics group (via affiliated Jinhe Capital in investment)[1]

Beyond the preview

Go deeper on Weimi Bio-Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weimi Bio-Tech.

Explore the full profile